ProfileGDS5678 / 1419367_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 92% 91% 92% 91% 93% 92% 90% 93% 95% 94% 91% 93% 92% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.6415192
GSM967853U87-EV human glioblastoma xenograft - Control 27.4461591
GSM967854U87-EV human glioblastoma xenograft - Control 37.683192
GSM967855U87-EV human glioblastoma xenograft - Control 47.5555891
GSM967856U87-EV human glioblastoma xenograft - Control 57.8994393
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.3636892
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.017590
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.941693
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.3279195
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.1561194
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.4288591
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.9180493
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.6514292
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.8254293